Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe?

Tomljenovic L, Spinosa JP, Shaw CA.

Curr Pharm Des. 2013;19(8):1466-87. Review.

PMID:
23016780
2.

Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.

Pomfret TC, Gagnon JM Jr, Gilchrist AT.

J Clin Pharm Ther. 2011 Feb;36(1):1-9. doi: 10.1111/j.1365-2710.2009.01150.x. Review.

PMID:
21198715
3.

Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.

Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, Smith JA.

Pharmacotherapy. 2011 Mar;31(3):280-97. doi: 10.1592/phco.31.3.280. Review.

PMID:
21361739
4.

Human papillomavirus vaccine: widening the scope for cancer prevention.

No JH, Kim MK, Jeon YT, Kim YB, Song YS.

Mol Carcinog. 2011 Apr;50(4):244-53. doi: 10.1002/mc.20657. Review.

PMID:
21465574
5.
6.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534.

PMID:
20139221
7.

Cervical cancers after human papillomavirus vaccination.

Beller U, Abu-Rustum NR.

Obstet Gynecol. 2009 Feb;113(2 Pt 2):550-2. doi: 10.1097/AOG.0b013e318191a54a.

PMID:
19155953
8.

Quadrivalent human papillomavirus vaccine.

Barr E, Tamms G.

Clin Infect Dis. 2007 Sep 1;45(5):609-7. Review.

PMID:
17682997
9.

Post-licensure monitoring of HPV vaccine in the United States.

Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF.

Vaccine. 2010 Jul 5;28(30):4731-7. doi: 10.1016/j.vaccine.2010.02.019. Review.

PMID:
20188681
10.

Human papillomavirus vaccines.

Satyaprakash A, Creed R, Ravanfar P, Mendoza N.

Dermatol Ther. 2009 Mar-Apr;22(2):150-7. doi: 10.1111/j.1529-8019.2009.01227.x. Review.

PMID:
19335726
11.

HPV vaccine: Cervarix.

Szarewski A.

Expert Opin Biol Ther. 2010 Mar;10(3):477-87. doi: 10.1517/14712591003601944. Review.

PMID:
20132062
12.

Currently approved prophylactic HPV vaccines.

Harper DM.

Expert Rev Vaccines. 2009 Dec;8(12):1663-79. doi: 10.1586/erv.09.123. Review.

PMID:
19943762
13.

Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.

Capri S, Gasparini R, Panatto D, Demarteau N.

Gynecol Oncol. 2011 Jun 1;121(3):514-21. doi: 10.1016/j.ygyno.2011.01.029.

PMID:
21334734
14.

Introducing human papillomavirus vaccines - questions remain.

Paavonen J, Lehtinen M.

Ann Med. 2008;40(3):162-6. doi: 10.1080/07853890701802404. Review.

PMID:
18382882
15.

Worldwide impact of the human papillomavirus vaccine.

Hakim AA, Dinh TA.

Curr Treat Options Oncol. 2009 Apr;10(1-2):44-53. doi: 10.1007/s11864-009-0094-4. Review.

PMID:
19387841
16.

Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis.

Lu B, Kumar A, Castellsagué X, Giuliano AR.

BMC Infect Dis. 2011 Jan 12;11:13. doi: 10.1186/1471-2334-11-13. Review.

17.

Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far.

Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM.

Vaccine. 2009 Dec 9;27(52):7270-81. doi: 10.1016/j.vaccine.2009.09.097. Review.

PMID:
19799849
18.

Cervical cancer prevention in the human papilloma virus vaccine era.

Ghazal-Aswad S.

Ann N Y Acad Sci. 2008 Sep;1138:253-6. doi: 10.1196/annals.1414.030.

PMID:
18837904
19.

Prevention strategies against the human papillomavirus: the effectiveness of vaccination.

Stanley M.

Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S19-23. Review.

PMID:
17938013
20.

Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure.

Miltz A, Price H, Shahmanesh M, Copas A, Gilson R.

PLoS One. 2014 Mar 3;9(3):e90348. doi: 10.1371/journal.pone.0090348. Review.

Items per page

Supplemental Content

Support Center